M&A / Deals Heart drug biotech Kardigan raises $400m in upscaled IPO PharmaphorumCardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 18, 2026) Pharmaphorum Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated. Cardiovascular Read full story Post navigation Previous: Cardio biotech Kardigan binds off $400M upsized IPONext: New biotech cAMPfield emerges with $180M to reshape IBD treatment Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
